MedTrace Logo

Clinical Investigation of the AcrySof® IQ PanOptix™ IOL

NCT03090256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2019-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness and safety of the AcrySof® IQ PanOptix™ Intraocular Lens (IOL) Model TFNT00 when implanted to replace the natural lens following cataract removal.

Conditions

  • Cataract

Interventions

DEVICE

AcrySof® IQ PanOptix™ IOL

Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Group Manager, Clinical Development · Alcon Japan, Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-11
Primary Completion
2018-02-13
Completion
2018-02-13
FDA Device
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090256 on ClinicalTrials.gov